PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
PTC Therapeutics (PTCT) Misses Q1 EPS by 32c, Revenues Beat
May 4, 2021 5:31 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.83), $0.32 worse than the analyst estimate of ($1.51). Revenue for the quarter came in at $117.94 million versus the consensus estimate of $98.8 million.
First Quarter 2021 Financial Highlights:
Total revenues were $117.9 million for the first quarter of 2021, compared to total revenues of $68.3 million for the first quarter of 2020, a 32% increase. Total revenue includes net product revenue of $91.3 million and collaboration and royalty revenue of $26.7 million in the first quarter of 2021.Translarna net product revenues were $46.5 million for the first quarter of 2021, compared to $40.5 million... More